[Atrial fibrillation therapy: different opinions]

Atrial fibrillation is the most common cardiac arrhythmia and its spread in the population is growing. The introduction of new drugs has widened the range of therapeutic strategies available to clinicians but there are different positions in the scientific community. The most accredited guidelines published in Chest suggest the use of new anticoagulant drugs in non valvular atrial fibrillation, while some independent drug information bulletins have a more conservative position. The editorial discusses this disagreement, urging government institutions to continue to monitor doctors' choices, while making the best sources of evidence available for health workers to make the most appropriate decisions.